Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio, Inc.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Atlas Venture

New Enterprise Associates

Alexandria Venture Investments

Wu Capital

MP Healthcare Venture Management

Surveyor Capital

Cormorant Asset Management

Qiming Venture Partners USA

Monashee Investment Management

Invus

Verition Fund Management

Fidelity

Point72

Sixty Degree Capital

Fidelity Management and Research Company

We’re pleased to announce that Korro Bio will be attending the TD Cowen 44th Annual Health Care Conference in Boston.

Our Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Monday, March 4, 2024, at 2:10 PM ET.

Tune in for a live webcast of the presentation at: https://ir.korrobio.com/

https://lnkd.in/eT4CnDQr

#KorroBio #TDCowen #TDCowenHealthCare Cowen Inc.

#ICYMI, the Korro team attended the Nasdaq Closing Bell Ringing Ceremony on Tuesday. Thank you to Nasdaq for hosting us and your collaboration. Our team had an incredibly humbling moment celebrating our success.

Here's to Korro’s ongoing innovation as we advance #RNAediting.

Missed the livestream? Catch the recording here: https://lnkd.in/eZkjHPRS 

#KorroBio #ClosingBell

We are pleased to announce the key highlights from our presentation at the J.P. Morgan Healthcare Conference last week. We shared data for our lead program in Alpha-1 Antitrypsin Deficiency (AATD) and our pipeline.  

To read more about our recent accomplishments, see the full press release: bit.ly/3HncrAX

To view our corporate presentation, go to: https://bit.ly/3vEWOCx 

#JPM2024 #JPMorganHealthcare #KorroBio

We invite you to tune in to the live webcast today at 11:15 am PT / 2:15 pm ET. Our CEO and President, Ram Aiyar, will share the corporate update at the J.P. Morgan Healthcare Conference. Learn more about our progress in expanding the frontiers of genetic medicines through #RNAediting.

To view the presentation, visit: bit.ly/41VtvHN

To listen to the webcast, go to: https://lnkd.in/g4n4jJqk

Vineet Agarwal Steve Colletti

#JPMorganHealthcare #JPM2024 #KorroBio

	Dec '21	Dec '22	Dec '23
net income	-21.96M -	-58.03M 164.27%	-81.17M 39.87%
depreciation and amortization	1.59M -	2.51M 57.43%	3.63M 44.56%
deferred income tax	28K -	-145K 617.86%	-15K 89.66%
stock based compensation	807K -	1.14M 41.26%	2.38M 108.86%
change in working capital	904K -	-633K 170.02%	4.28M 776.62%
accounts receivables
inventory
accounts payables	56K -	1.75M 3,033.93%	3.10M 76.64%
other working capital	848K -	-2.39M 381.60%	1.18M 149.54%
other non cash items	-13.47M -	1.51M 111.24%	3.61M 138.44%
net cash provided by operating activities	-32.09M -	-53.65M 67.15%	-67.28M 25.42%
investments in property plant and equipment	-4.45M -	-5.21M 17.20%	-7.84M 50.35%
acquisitions net	-29.23M -
purchases of investments	-35.07M -	-37.21M 6.12%
sales maturities of investments	29.23M -	53.48M 82.96%	19M 64.48%
other investing activites	-29.22M -
net cash used for investing activites	-39.50M -	11.06M 128.00%	11.16M 0.94%
debt repayment
common stock issued	1.36M -	62K 95.43%	117.25M 189,012.90%
common stock repurchased
dividends paid
other financing activites	-30K -	-44K 46.67%	24.35M 55,443.18%
net cash used provided by financing activities	115.94M -	18K 99.98%	187.76M 1,043,016.67%
effect of forex changes on cash
net change in cash	44.35M -	-42.57M 195.98%	131.64M 409.26%
cash at beginning of period	39.69M -	84.04M 111.73%	41.48M 50.65%
cash at end of period	84.04M -	41.48M 50.65%	173.12M 317.39%
operating cash flow	-32.09M -	-53.65M 67.15%	-67.28M 25.42%
capital expenditure	-4.45M -	-5.21M 17.20%	-7.84M 50.35%
free cash flow	-36.54M -	-58.86M 61.07%	-75.12M 27.63%

KRRO

COM:KORROBIO

Korro Bio

Last Close

69.10

08/11 21:00

Market Cap

385.94M

Beta: -

Volume Today

91.75K

Avg: -

Preview